Posts

Pivotal Bio Venture Partners closes $389 million fund, totaling $689 million in commitments

Pivotal Bio Venture Partners closes $389 million fund, ...

Dec 22, 2023

Pivotal bioVenture Partners has successfully concluded its second fund, securing...

GSK returns to Hansoh and pays $185 million upfront for an additional ADC

GSK returns to Hansoh and pays $185 million upfront for...

Dec 22, 2023

The ongoing surge of interest in antibody-drug conjugates (ADCs) remains unabate...

Compass Unveils Safety Data For Psilocybin Phase 2 PTSD Study

Compass Unveils Safety Data For Psilocybin Phase 2 PTSD...

Dec 22, 2023

In less than a week following the submission of the historic first request for a...

Sanofi forced to abandon Lead ADC Tusamitamab Ravtansine After Phase 3 Trial Disappointment

Sanofi forced to abandon Lead ADC Tusamitamab Ravtansin...

Dec 22, 2023

Sanofi, a prominent figure in the pharmaceutical realm, finds itself grappling w...

FDA approves Wainua for Rare Disease Treatment

FDA approves Wainua for Rare Disease Treatment

Dec 22, 2023

In a milestone announcement, the U.S. Food and Drug Administration (FDA) has gra...

Ionis and AstraZeneca drug gains FDA approval for Hereditary Transthyretin Amyloidosis

Ionis and AstraZeneca drug gains FDA approval for Hered...

Dec 22, 2023

Ionis Pharmaceuticals and AstraZeneca are capping off the year with a notable ac...

AbbVie to Shell Out $8.7B to Purchase Cerevel

AbbVie to Shell Out $8.7B to Purchase Cerevel

Dec 22, 2023

AbbVie has entered into an agreement to purchase Cerevel Therapeutics for $8.7 b...

Jazz Pharmaceuticals Faces Setback in JZP150 Phase II Trial for PTSD Treatment

Jazz Pharmaceuticals Faces Setback in JZP150 Phase II T...

Dec 22, 2023

Jazz Pharmaceuticals recently released the top-line findings from Phase II trial...

Cadonilimab by Akeso for Esophageal Squamous Cell Carci...

Dec 22, 2023

Cadonilimab is under clinical development by Akeso and currently in Phase II for...

SOR-007 by Nanology for Metastatic Adenocarcinoma of Th...

Dec 22, 2023

SOR-007 is under clinical development by Nanology and currently in Phase II for ...

MRNA-2752 by Moderna for Transitional Cell Cancer (Urot...

Dec 22, 2023

MRNA-2752 is under clinical development by Moderna and currently in Phase I for ...

Imvotamab by IGM Biosciences for Rheumatoid Arthritis: ...

Dec 22, 2023

Imvotamab is under clinical development by IGM Biosciences and currently in Phas...

XB-002 by Exelixis for Breast Cancer: Likelihood of App...

Dec 22, 2023

XB-002 is under clinical development by Exelixis and currently in Phase II for B...

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Li...

Dec 22, 2023

Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently ...

Runimotamab by Genentech USA for Solid Tumor: Likelihoo...

Dec 22, 2023

Runimotamab is under clinical development by Genentech USA and currently in Phas...

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Ca...

Dec 22, 2023

IDE-161 is under clinical development by Ideaya Biosciences and currently in Pha...